Laurus Labs (NSE:LAURUSLABS, BOM:540222) has completed an investment of 833 million Indian rupees in its joint venture company KRKA Pharma, according to a Saturday filing to the Indian stock exchanges.
The company has acquired 83,300,000 equity shares of KRKA at a face value of 10 rupees via a rights issue.
According to a disclosure earlier in the month, Laurus Lab's joint venture partner KRKA d.d., Novo mesto, Slovenia will also invest 867 million rupees in KRKA.
Both joint venture partners will maintain their shareholding ratio of 51:49 between KRKA d.d., Novo mesto, and Laurus Labs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.